116 related articles for article (PubMed ID: 20577933)
1. Treatment and prevention of secondary CNS lymphoma.
Nagpal S; Glantz MJ; Recht L
Semin Neurol; 2010 Jul; 30(3):263-72. PubMed ID: 20577933
[TBL] [Abstract][Full Text] [Related]
2. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.
Herrlinger U; Glantz M; Schlegel U; Gisselbrecht C; Cavalli F
Semin Oncol; 2009 Aug; 36(4 Suppl 2):S25-34. PubMed ID: 19660681
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
[TBL] [Abstract][Full Text] [Related]
4. To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin's lymphoma.
Lim HY; Thiel E; Glantz MJ
Curr Opin Oncol; 2008 Sep; 20(5):495-501. PubMed ID: 19106650
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma.
Bierman P; Giglio P
Hematol Oncol Clin North Am; 2005 Aug; 19(4):597-609, v. PubMed ID: 16083825
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options.
Ferreri AJ; Assanelli A; Crocchiolo R; Ciceri F
Hematol Oncol; 2009 Jun; 27(2):61-70. PubMed ID: 19247977
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system.
Jahnke K; Thiel E; Martus P; Schwartz S; Korfel A
Ann Hematol; 2006 Jan; 85(1):45-50. PubMed ID: 16132909
[TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis, prophylaxis and treatment of central nervous system involvement by non-Hodgkin lymphoma in HIV-infected patients].
Miralles P; Berenguer J; Ribera JM;
Med Clin (Barc); 2010 Sep; 135(9):417-22. PubMed ID: 19628233
[TBL] [Abstract][Full Text] [Related]
10. Secondary central nervous system lymphoma: risk factors and prophylaxis.
Montoto S; Lister TA
Hematol Oncol Clin North Am; 2005 Aug; 19(4):751-63, viii. PubMed ID: 16083835
[TBL] [Abstract][Full Text] [Related]
11. CNS prophylaxis in lymphoma: who to target and what therapy to use.
Hill QA; Owen RG
Blood Rev; 2006 Nov; 20(6):319-32. PubMed ID: 16884838
[TBL] [Abstract][Full Text] [Related]
12. Results of combined-modality therapy for primary and secondary malignant lymphoma of the central nervous system (CNS).
Kawamura T; Koga S; Okamoto M; Kanno T; Iwamura H
Radiat Med; 2001; 19(3):145-9. PubMed ID: 11467381
[TBL] [Abstract][Full Text] [Related]
13. Statistical and trial design considerations in central nervous system prophylaxis studies.
Smith JA; Glantz M
Semin Oncol; 2009 Aug; 36(4 Suppl 2):S69-76. PubMed ID: 19660685
[TBL] [Abstract][Full Text] [Related]
14. Localized stage non-Hodgkin's lymphoma of the testis: a retrospective study of 16 cases.
Ostronoff M; Soussain C; Zambon E; Moran A; Droz JP; Bosq J; Bayle C; Cosset JM; Hayat M
Nouv Rev Fr Hematol (1978); 1995; 37(5):267-72. PubMed ID: 8700650
[TBL] [Abstract][Full Text] [Related]
15. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Pfeifer H; Wassmann B; Hofmann WK; Komor M; Scheuring U; Brück P; Binckebanck A; Schleyer E; Gökbuget N; Wolff T; Lübbert M; Leimer L; Gschaidmeier H; Hoelzer D; Ottmann OG
Clin Cancer Res; 2003 Oct; 9(13):4674-81. PubMed ID: 14581336
[TBL] [Abstract][Full Text] [Related]
16. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-hodgkin lymphoma.
Desai J; Mitnick RJ; Henry DH; Llena J; Sparano JA
Cancer; 1999 Nov; 86(9):1840-7. PubMed ID: 10547559
[TBL] [Abstract][Full Text] [Related]
17. Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals.
Mazhar D; Stebbing J; Bower M
Expert Rev Anticancer Ther; 2006 Mar; 6(3):335-41. PubMed ID: 16503851
[TBL] [Abstract][Full Text] [Related]
18. An update on primary central nervous system lymphoma.
Iwamoto FM; DeAngelis LM
Hematol Oncol Clin North Am; 2006 Dec; 20(6):1267-85. PubMed ID: 17113462
[TBL] [Abstract][Full Text] [Related]
19. Primary CNS lymphoma.
Maher EA; Fine HA
Semin Oncol; 1999 Jun; 26(3):346-56. PubMed ID: 10375091
[TBL] [Abstract][Full Text] [Related]
20. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.
Gill S; Herbert KE; Prince HM; Wolf MM; Wirth A; Ryan G; Carney DA; Ritchie DS; Davies JM; Seymour JF
Br J Haematol; 2009 Oct; 147(1):83-8. PubMed ID: 19694718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
